Agomab Therapeutics NV, headquartered in Ghent, Belgium, is a clinical-stage biopharmaceutical company dedicated to pioneering treatments for fibro-stenotic and regenerative diseases. Established in 2017, the company leverages its deep understanding of growth factor biology to develop a pipeline of small molecules and antibodies designed to modulate pathways that drive fibrosis and tissue repair. Agomab’s therapeutic strategy focuses on two primary pathways: the Transforming Growth Factor beta (TGF-β) pathway and the Hepatocyte Growth Factor (HGF) pathway. Their lead clinical candidate, AGMB-129, is a gut-restricted, small-molecule inhibitor of ALK5 (TGF-β receptor 1) currently being evaluated for the treatment of fibrostenotic Crohn’s disease. By inhibiting ALK5 locally in the gastrointestinal tract, the company aims to prevent and reverse the fibrotic complications that often lead to surgery in Crohn's patients. In addition to its gastrointestinal programs, Agomab is developing AGMB-447, an inhaled ALK5 inhibitor for Idiopathic Pulmonary Fibrosis (IPF), and AGMB-101, a MET-agonistic antibody designed for regenerative applications in organ failure. The company’s approach combines precision medicinal chemistry with a focus on high unmet medical needs in chronic inflammatory conditions. Led by CEO Tim Knotnerus, Agomab has secured significant backing from prominent life sciences investors and successfully transitioned to a public company on the NASDAQ exchange to fund its expanding clinical trials and research initiatives.
The sum of declared dividends issued by a company for every ordinary share outstanding.
Dividend Yield is a financial ratio that shows how much a company pays out in dividends each year relative to its share price in the last twelve months. In the absence of any capital gains, the dividend yield is the return on investment for a stock.
It is another way that companies have to remunerate their shareholders, being an alternative to dividends. Shows the % of repurchases per share made in the last 12 months in relation to the share price.
Sum of Dividend Yield and BuyBack Yield to show the total return that the shareholder received in the last 12 months in relation to the share price.
The dividend payout ratio is the ratio of the total amount of dividends paid out to shareholders relative to the net income of the company. It is the percentage of earnings paid to shareholders via dividends.
Retained earnings (RE) are the amount of net income left over for the business after it has paid out dividends to its shareholders and are an important variable for assessing a company's financial health because it shows the net income that a company has saved over time, and therefore has the ability to reinvest in the business or distribute to shareholders.
...and much more!